A list of ongoing and future research projects is available here and a spreadsheet is embedded below:
RESEARCH EXPERIENCE
2012-2014
Principal investigator. Incidence of insufficient response to pneumococcal immunizations and selective antibody deficiency with normal immunoglobulins (SADNI) among patients with chronic sinusitis and recurrent otitis media
2011-2013
Principal investigator. Investigating the etiology of chronic urticaria and the role of H. pylori, vitamin D, anti-IgE receptor antibodies.
2011-2013
Principal investigator. Characteristics of the Professional Use of the Social Network Twitter by Allergists and Immunologists. University of Chicago. N. Fenny, V. Dimov, R. Wolf.
2010-2012
Investigator. Childhood Rhinitis, Skin Testing, and Effects of Breast Milk Exposure. University of Chicago. R. Wolf, V. Dimov.
2010-2012
Investigator. AsthmaNet, multi-centered network examining novel therapeutic approaches to asthma in children and adults, funded by the National Heart, Lung and Blood Institute (NHLBI).
Principal investigator. Patient reception of iPad as a clinical education tool. University of Chicago. V. Dimov, A. Nickels, R. Wolf.
2008-2010
Investigator. The Effects of the PPAR-gamma Agonist Rosiglitazone on Airway Hyperreactivity. Creighton University Division of Allergy & Immunology, Omaha, Nebraska. Wichman T, Casale T. Available at: http://clinicaltrials.gov/ct2/show/NCT00614874.
2008-2009
Principal Investigator. Online Case-based curriculum of Allergy and Immunology for education of fellows in training. Creighton University Division of Allergy & Immunology, Omaha, Nebraska, Louisiana State University Health Sciences Center (Shreveport).
2007-2008
Investigator. Podcast as a Medical Education Tool in an Internal Medicine Residency Program. Auron M, Dimov V, Nielsen C. Cleveland Clinic, Cleveland, Ohio.
2006-2008
Principal Investigator. Risk factors for Acute Renal Failure after Noncardiac Surgery (RANCS). A retrospective review of 21,000 patients at the Cleveland Clinic. Dimov V, Usmani A, Jaffer A, Schreiber M, Kumar A, Lascano M, Rajamanickam A, V. Molina, Hixson E. Cleveland Clinic, Cleveland, Ohio.
2006-2008
Principal Investigator. Awareness of Renal Function Status and Chronic Kidney Disease in Patients with Diabetes (ARF CD). Dimov V, Kumar A. Cleveland Clinic, Cleveland, Ohio.
2006-2007
Principal Investigator. How to Stay Up-to-date with the Literature: A Web Feeds Portal for Scientific Journals. Dimov V, Kumar A. Cleveland Clinic, Cleveland, Ohio.
2005-2007
Investigator. Perioperative beta-blocker dose titration and clinical outcomes during major noncardiac surgery. Aneja A, Harte B, C. Phillips, Dimov V, Usmani A, Michota F, Jaffer A, Kumar A. Cleveland Clinic, Cleveland, Ohio.
2005-2006
Investigator. INCREASE, Optimization of beta-blocker use in the perioperative period of noncardiac surgery. Aneja A, Harte B, Hixson E, Jaffer A, Singh V, Dimov V. Cleveland Clinic, Cleveland, Ohio.
2005-2006
Investigator. Improvement of Perioperative Beta-blocker Use through Electronic Medical Record-based Best Practice Alert (PBB & BPA Study). Aneja A, Harte B, Hixson E, Jaffer A, Singh V, Dimov V. Cleveland Clinic, Cleveland, Ohio.
2004-2006
Principal Investigator. A Web Log Software Platform as a Medium for Medical Education. Dimov V, Kumar A, Uzunova-Dimova K. Case Western Reserve University (St. Vincent/St. Luke) and Cleveland Clinic, Cleveland, Ohio.
2004
Principal Investigator. Assessment of Effectiveness of a Blog Website Created and Maintained by the Medical Residents for Improving Postgraduate Medical Education. Dimov V, Case Western Reserve University (St.Vincent/St.Luke) Internal Medicine Residency Program, Cleveland, Ohio
2003
Investigator. West Nile Virus Infection - the Experience of Hospitals in Cuyahoga County, Ohio. A. Brobbey, Case Western Reserve University, Cleveland, Ohio.
2001
Investigator. Tidal Breathing Analysis in Evaluating Bronchial Obstruction in Children. Filtchev S, Medical University Sofia.
1999-2000
Investigator. Intercontinental Childhood ITP Study Group. Registry of Children with Idiopathic Thrombocytopenic Purpura. Tom Kuhne, Basel University, Switzerland. Prof. Kalev I, Medical University Sofia. Results published in the Lancet, Vol.358, Dec 22/29, 2001.
2000
Investigator. Cytological Comparison of Nasal Smear and Bronchoalveolar Lavage Fluid in Children with Rhinosinusitis and Asthma. Ulevinov N, Medical University Sofia.
2000
Investigator. Pulmonary Complications after Influenza Virus Infection. Prof. Kalev I, Medical University Sofia.
1998
Investigator. Molecular Diagnosis of Hemophilia A in Bulgaria by DNA Analysis Using Polymorphisms Within And Outside Factor VIII Gene. Prof. I.Kremenski, Medical University Sofia.
1996
Investigator. Jarisch-Herxheimer Reaction during Treatment of Patients with Syphilis. Prof. K. Pramatarov, Dermatology and Sexual Transmitted Diseases Hospital, Medical University Sofia.
CLINICAL RESEARCH TRIALS EXPERIENCE
2011-2013
A 6-Month Safety and Benefit Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in The Treatment of 6,200 Pediatric Subjects 4-11 Years Old with Persistent Asthma SAS115358, VESTRI Trial, GlaxoSmithKline (GSK) Research & Development.
2009-2010
Investigator. Pfizer B0871006. A Study to Investigate The Efficacy and Safety of Inhaled PF-00241939 Using CRC-749 Dry Powder Inhaler. Casale T, Creighton University Division of Allergy & Immunology.
2009-2010
Investigator. Schering-Plough P05234. A M Multi-Center, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma. Casale T, Creighton University Division of Allergy & Immunology.
2009-2010
Investigator. A Phase II, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR 444A) in Adult Patients with Asthma who are Inadequately Controlled on Inhaled Corticosteroids. Casale T, Creighton University Division of Allergy & Immunology.
2009-2010
Investigator. Capnia Protocol C218. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used Four Times a Day in the Symptomatic Treatment of Seasonal Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.
2009-2010
Investigator. CQMF149A2210. A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler (500/400μg) and mometasone furoate Twisthaler (400μg) in adolescent and adult patients with persistent asthma. Casale T, Creighton University Division of Allergy & Immunology.
2009-2010
Investigator. Novartis Protocol CNVA237. A 52-Week Treatment, Randomized, Double-Blind, Placebo-Controlled, With Open Label Tiotropium, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of NVA237 In Patients With Chronic Obstructive Pulmonary Disease. Casale T, Creighton University Division of Allergy & Immunology.
2009-2010
Investigator. Pfizer PF-0419183. A Phase 2A, Randomized, Double-Blind (3rd Party Open), Double-Dummy, Placebo and Active Controlled 5-way Crossover Study to Assess the Bronchodilatory Action, Safety, Toleration and Pharmacokinetics of Single Oral Doses of PF-04191834 in Asthmatic Patients. Casale T, Creighton University Division of Allergy & Immunology.
2008-2010
Investigator. Boehringer Ingelheim 1012.57. A Multi-Center, Randomized Study Starting with a 4-week, 2-way crossover double-blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI followed by a 4-week Open-Label Combivent Respimat Treatment Phase when All Study Drugs are Used for Symptom Relief “as needed” in Patients With Moderate-to Severe Asthma (GINA 2207 Treatment Steps 3 to 5). Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. GSK FFR110537. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110 mcg in Adults and Adolescents 12 years of Age and Older with Perennial Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Stallergenes V061.08. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety Of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. MedImmune MI-CP143. Phase IIa Randomized Double-Blind Placebo-Controlled Dose-Escalating Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Merck. The Effect of Montelukast In-Vitro on Basophil, Histamine and Leukotriene, IL-4 and IL-13 Release in Subjects with Allergic Rhinitis or Allergic Asthma. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Capnia C215. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Merck 388-00. A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MKL-0476 in Patients with Chronic Asthma. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Greer Labs. (SLIT 07-01). Parallel, Randomized Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused by Ragweed Pollen. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Capnia C213. A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Effect of Nasal Carbon Dioxide on Nasal Congestion via Acoustic Rhinometry in Subjects with Perennial Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of lung Disease After Treatment with Xolair. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. A randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase II Study to Determine the Safety and Efficacy of AMG317 I Subjects with Moderate to Severe Asthma. Amgen, Incorporated. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. A randomized, Double-Blinded, Placebo Controlled, Parallel group, Multi-center Study to assess Safety Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous doses of QAX576 in Moderate Persistent Allergic Asthmatics following Inhaled Corticosteroid Withdrawal. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.
2007-2008
Investigator. Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency And Acute Abdominal or Facial HAE Attacks. ZLB Behring. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. C-05-69 Safety Study of Olopatadine Nasal Spray. Alcon Research, Ltd. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. A Randomized, Placebo-Controlled Double-Blind Study to Test the efficacy and Safety/Tolerability of Grass MATAMPL. Allergy Therapeutics. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Study the Efficacy and Safety of Oral Microencapsulated Ragweed Pollen extract Administered Prior and During Ragweed Pollen Season. Curaologic. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. A 26-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of 2 Doses of Indacaterol (selected from 75, 150, 300 and 600 ug/od) in Patients with Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 ug BID) and Open Label Tiotropium (18 ug od) as Active Controls.Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. A Randomized, Placebo-Controlled Double-Blind Study to Test the Efficacy and Safety/Tolerability of Ragweed MATAMPL. Allied Therapeutics. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. The Effect of Roflumilast In-Vitro on Basophil, Histamine and Leukotriene, IL-4 and IL-13. Altana, Incorporated. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. A Phase IIa, Multi-Center, Randomized, Double-Blind Placebo-Controlled, Parallel, Dose-finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab on Subjects with Refractory Asthma. Abbott Labs. Casale T, Creighton University Division of Allergy & Immunology. Casale T, Creighton University Division of Allergy & Immunology.
2008
Investigator. A 26-week Treatment, Randomized Multicenter, Double-Blind, Double-Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 ug od) in Patients with Moderate to Severe Persistent Asthma, Using Salmeterol (50 ug bid) as an Active Control. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.
2002-2003
Investigator. SD-039-0682 (SAMBA). A 12-week, randomized, double-blind, parallel-group, multicentre, phase-III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 80/4.5 µg 2 inhalations b.i.d., delivered dose) in children with asthma. AstraZeneca R & D, Lund, Sweden. Prof. Kalev I, Medical University Sofia.
2001-2002
Investigator. SD-039-0673 (STAY). Efficacy and Safety of Budesonide/Formoterol (Symbicort)) Turbuhaler as Single Therapy in Patients Aged 6-80 years with Mild-Moderate Asthma. Comparison with Symbicort Turbuhaler and Pulmicort Turbuhaler as Maintenance Therapy, Both Complemented with Bricanyl Turbuhaler. International, Multicentre, Double blind, Randomized, Active-controlled Study. L. Laxmyr, AstraZeneca Research & Development, S-221 87 Lund, Sweden. Prof. Kalev I, Medical University Sofia.
2001
Investigator. HMR 3647B/2001. Multicentre, Phase II, Open Label Study of the Efficacy, Safety, Acceptability, and Pharmacokinetics of Telithromycin, after repeated Oral Administration of Either of Two Doses, Once Daily, for 5 days or 7 days, in the Treatment of Respiratory Tract Infections in Children of 6 months to 12 years. Dr Emmanuelle Butticaz-Iroudayssamy, Aventis Pharma, Hoechst Marion Roussel R & D, Romainville, France. D. Youngblood, Quintiles, Inc., Kansas City, MO, USA. Prof. Kalev I, Medical University Sofia.
2000-2001
Investigator. SAM 40012 International, Multicentre, Randomized, Parallel Group Comparison of Three Treatments: 1. Salmeterol and Fluticasone, 2. Fluticasone 200 mcg bd, 3. Fluticasone 100 mcg bd in Children aged 4-11 years with Asthma. L. Norcross, GlaxoSmithKline Research and Development, Uxbridge, UK. Prof. Kalev I, Medical University Sofia.
2000-2001
Investigatort. Budesonide Efficacy and Safety in Children aged 5-15 years with Asthma over a 26-week Treatment Period. For Astra Zeneca Research. Prof. Kalev I, Medical University Sofia.
1999-2000
Investigator. FAS 30009 International, Multicentre, Randomized Study to Assess the Long Term Safety of Fluticasone Propionate Compared with Sodium Cromoglycate in Children aged 12-47 Months with Asthma over a 52-week Treatment Period. P. Davis, GlaxoSmithKline R & D, Uxbridge, UK. Prof. Kalev I, Medical University Sofia. Results presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 58th Annual Meeting - March 1-6, 2002, New York; published in the Journal of Allergy and Clinical Immunology, part 2, Vol.109, No 1, Jan 2002.
1999
Investigator. Clarithromycin Use, Safety and Efficacy in Children aged 1-12 years with Infections of Upper and Lower Respiratory Tract. For Abbot Laboratories. Prof. I.Kalev, Medical University Sofia.
1999
Investigator. Midecamycin Effect in Children aged 2 to 12 years with Otitis Media, Bronchitis and Pneumonia. Prof. Kalev I, Medical University Sofia.
PUBLICATIONS
Click here to see the complete list.
Published: 06/21/2008
Updated: 08/17/2014
